Clinical Research Directory

Inclusion Criteria: 1. Voluntarily participate in this clinical study, understand the research procedures and be able to sign the informed consent in writing; 2. Age ≥ 18 years old, gender is not limited; 3. Eastern Cooperative Oncology Group (ECOG) performance status score ≤2; 4. Expected survival time ≥ 2 years; 5. High-risk NMIBC diagnosed by previous pathological biopsy 6. ineligible or unwilling to undergo radical cystectomy; 7. The level of organ function is good. Exclusion Criteria: 1. Currently receiving study treatment in other clinical trials or less than 4 weeks from last participation to the first administration of this study; 2. Upper urinary tract tumor detected by CTU or MRU during screening period, urethral prostate tumor detected by cystoscopy, or other concomitant malignant tumors within 5 years before the first administration; 3. Previous medical history or examination suggests active tuberculosis within 1 year prior to the first dose; 4. Serious infection within 4 weeks before the first administration, or undefined fever\>38.5 ℃ during screening/before the first administration; 5. Obvious urinary tract infections and gross hematuria, indicating safety issues assessed by the investigators; 6. Patients who discontinued treatment due to adverse reactions such as toxemia, systemic infection or urinary incontinence during previous BCG treatment